TEVA vs. GSK, TAK, ARGX, BNTX, BGNE, SMMT, GMAB, VTRS, ITCI, and MRNA
Should you be buying Teva Pharmaceutical Industries stock or one of its competitors? The main competitors of Teva Pharmaceutical Industries include GSK (GSK), Takeda Pharmaceutical (TAK), argenx (ARGX), BioNTech (BNTX), BeiGene (BGNE), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Intra-Cellular Therapies (ITCI), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.
Teva Pharmaceutical Industries vs.
Teva Pharmaceutical Industries (NYSE:TEVA) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, community ranking, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.
Teva Pharmaceutical Industries presently has a consensus target price of $22.13, indicating a potential upside of 1.21%. GSK has a consensus target price of $43.25, indicating a potential upside of 28.10%. Given GSK's higher probable upside, analysts plainly believe GSK is more favorable than Teva Pharmaceutical Industries.
GSK has higher revenue and earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.
54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, GSK had 2 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 13 mentions for GSK and 11 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 1.07 beat GSK's score of 0.67 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.
Teva Pharmaceutical Industries has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.
GSK has a net margin of 7.97% compared to Teva Pharmaceutical Industries' net margin of -5.73%. GSK's return on equity of 50.62% beat Teva Pharmaceutical Industries' return on equity.
Teva Pharmaceutical Industries received 507 more outperform votes than GSK when rated by MarketBeat users. Likewise, 67.82% of users gave Teva Pharmaceutical Industries an outperform vote while only 57.13% of users gave GSK an outperform vote.
Summary
GSK beats Teva Pharmaceutical Industries on 12 of the 19 factors compared between the two stocks.
Get Teva Pharmaceutical Industries News Delivered to You Automatically
Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Teva Pharmaceutical Industries Competitors List
Related Companies and Tools
This page (NYSE:TEVA) was last updated on 1/22/2025 by MarketBeat.com Staff
